Craniofacial effects of alendronate treatment in growing osteogenesis imperfecta mice.
Published: 2006
Language: eng
Number of pages: 104
ISBN-13: 9780494210901
Description: Bisphosphonates have shown promise in reducing fractures in children with osteogenesis imperfecta (OI). To date, effects of these drugs on the growing craniofacial skeleton have not been investigated. To address this, alendronate (ALN) was evaluated in the growing oim/oim mouse, a model of moderate-to-severe OI. Wildtype (+/+) and oim/oim  mice received saline or ALN at a dosage of 26 mug ALN/kg/day from 6-12 weeks of age. Skulls (n=49) were scanned at 12 weeks with microCT to create 3D reconstructions. Cranial and mandibular landmarks were digitized and statistical shape analysis methods compared cranial and mandibular size and shape between groups. Back-scattered electron imaging of the spheno-occipital synchondrosis evaluated drug effects on bone quality. oim/oim mice exhibited significant skull dysmorphology with parallels to human OI. The anti-resorptive activity of ALN does not appear to compromise craniofacial growth. ALN treatment normalized FM morphology in oim/oim mice through improvements in skull bone quality.
Notes: Source: Masters Abstracts International, Volume: 45-03, page: 1439.

Thesis (M.Sc.)--University of Toronto, 2006.

Electronic version licensed for access by U. of T. users.

ROBARTS MICROTEXT copy on microfiche.